{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:37:14Z","timestamp":1782549434452,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the healthcare business of Merck KGaA, Darmstadt, Germany"},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.urolonc.2025.05.014","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T03:53:13Z","timestamp":1752724393000},"page":"594.e19-594.e29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6303-5285","authenticated-orcid":false,"given":"Helen H.","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanny B.","family":"Aragon-Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vlahiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiemeka","family":"Ike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrin","family":"Benjumea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anran","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbek","family":"Gharibian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.05.014_bib0001","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0002","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0003","unstructured":"SEER*Explorer. Cancer stat facts: bladder cancer. Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html (Accessed November 25, 2024)."},{"key":"10.1016\/j.urolonc.2025.05.014_bib0004","doi-asserted-by":"crossref","first-page":"735","DOI":"10.21037\/tau.2016.08.23","article-title":"Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery","volume":"5","author":"Abufaraj","year":"2016","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0005","unstructured":"SEER*Explorer. Urinary bladder (invasive & in situ) SEER 5-year relative survival rates, 2012-2018. Available online:https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=71&data_type=4&graph_type=5&compareBy=stage&chk_stage_104=104&chk_stage_105=105&chk_stage_106=106&chk_stage_107=107&series=9&sex=1&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on&hdn_view=0#graphArea (Accessed November, 09)."},{"key":"10.1016\/j.urolonc.2025.05.014_bib0006","unstructured":"National Comprehensive Cancer Network. Bladder cancer (Version 4.2024). Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf (Accessed June 14, 2024)."},{"key":"10.1016\/j.urolonc.2025.05.014_bib0007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0008","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0009","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0010","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0011","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0012","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.urolonc.2025.05.014_bib0013","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1200\/JCO.2022.40.16_suppl.4577","article-title":"Defining \u201cplatinum-ineligible\u201d patients with metastatic urothelial cancer (mUC)","volume":"40","author":"Gupta","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0014","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0015","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0016","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15 suppl","key":"10.1016\/j.urolonc.2025.05.014_bib0017","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2018.36.15_suppl.4504","article-title":"Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC)","volume":"36","author":"Rosenberg","year":"2018","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.1016\/j.urolonc.2025.05.014_bib0018","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2018.36.15_suppl.4503","article-title":"First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt)","volume":"36","author":"Siefker-Radtke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0019","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"17 suppl","key":"10.1016\/j.urolonc.2025.05.014_bib0020","doi-asserted-by":"crossref","first-page":"LBA4619","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4619","article-title":"Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)","volume":"41","author":"Loriot","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0021","unstructured":"Gilead Sciences. Gilead provides update on phase 3 TROPiCS-04 Study. News Release. Available online: https:\/\/www.gilead.com\/news\/news-details\/2024\/gilead-provides-update-on-phase-3-tropics-04-study (Accessed November 25, 2024)."},{"key":"10.1016\/j.urolonc.2025.05.014_bib0022","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. Available online:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2 (Accessed November 25, 2024)."},{"key":"10.1016\/j.urolonc.2025.05.014_bib0023","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, Agrawal M, Est\u00e9vez M, Estola E, et al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research [preprint]. arXiv:2001.09765. doi:10.48550\/arXiv.2001.09765."},{"key":"10.1016\/j.urolonc.2025.05.014_bib0024","unstructured":"Flatiron. Real-World Data. Available online: https:\/\/flatiron.com\/real-world-evidence\/ (Accessed November 25, 2024)."},{"key":"10.1016\/j.urolonc.2025.05.014_bib0025","doi-asserted-by":"crossref","unstructured":"Ma X, Long L, Moon S, Adamson B.J.S, Baxi S.S. Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR [preprint]. medRxiv 2020.03.16.20037143. doi:10.1101\/2020.03.16.20037143.","DOI":"10.1101\/2020.03.16.20037143"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0026","unstructured":"SAS. Version 9.4 [software]. SAS Institute Inc. https:\/\/support.sas.com\/software\/94\/."},{"key":"10.1016\/j.urolonc.2025.05.014_bib0027","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0028","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0029","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2025.05.014_bib0030","first-page":"LBA7","article-title":"Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase III CheckMate 901 trial","volume":"34","author":"van der Heijden","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2020.12.002","article-title":"Real-world treatment patterns and overall survival in locally advanced and metastatic urothelial tract cancer patients treated with chemotherapy in Denmark in the preimmunotherapy era: a nationwide, population-based study","volume":"24","author":"Omland","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0032","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12894-022-01139-9","article-title":"Comparison of full-dose gemcitabine\/cisplatin, dose-reduced gemcitabine\/cisplatin, and gemcitabine\/carboplatin in real-world patients with advanced urothelial carcinoma","volume":"22","author":"Sugimoto","year":"2022","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0033","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.7150\/jca.23162","article-title":"A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic urothelial cancer patients in Germany","volume":"9","author":"Niegisch","year":"2018","journal-title":"J Cancer"},{"issue":"4 suppl","key":"10.1016\/j.urolonc.2025.05.014_bib0034","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1200\/JCO.2024.42.4_suppl.702","article-title":"Identification of patients with metastatic urothelial cancer not able to receive maintenance avelumab","volume":"42","author":"Jackson-Spence","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0035","article-title":"Uptake of maintenance immunotherapy and changes in upstream treatment selection among patients with urothelial cancer","volume":"6:e238395","author":"Mamtani","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6 suppl","key":"10.1016\/j.urolonc.2025.05.014_bib0036","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1200\/JCO.2023.41.6_suppl.483","article-title":"US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2025.05.014_bib0037","doi-asserted-by":"crossref","first-page":"S1215","DOI":"10.1016\/j.annonc.2023.09.1036","article-title":"Avelumab first-line maintenance (1LM) for locally advanced or metastatic urothelial carcinoma (la\/mUC): treatment (tx) patterns and real-world (rw) outcomes in the US","volume":"34","author":"Carson","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.urolonc.2025.05.014_bib0038","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2024.42.4_suppl.697","article-title":"Avelumab first-line maintenance therapy for locally advanced\/metastatic urothelial carcinoma: results from the real-world US PATRIOT-II study","volume":"42","author":"Grivas","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.05.014_bib0039","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clgc.2023.06.008","article-title":"Response and outcomes of maintenance avelumab after platinum-based chemotherapy (PBC) in patients with advanced urothelial carcinoma (aUC): \u201creal world\u201d experience","volume":"21","author":"Bakaloudi","year":"2023","journal-title":"Clin Genitourin Cancer"},{"issue":"4 suppl","key":"10.1016\/j.urolonc.2025.05.014_bib0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.2024.42.4_suppl.561","article-title":"Updated results from AVENANCE: real-world effectiveness of avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) and analysis of subsequent treatment","volume":"42","author":"Barthelemy","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4 suppl","key":"10.1016\/j.urolonc.2025.05.014_bib0041","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2024.42.4_suppl.558","article-title":"Subgroup analyses from READY: real-world data from an Italian compassionate use program (CUP) of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"42","author":"Bracarda","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4 suppl","key":"10.1016\/j.urolonc.2025.05.014_bib0042","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2024.42.4_suppl.537","article-title":"Outcomes in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin (EV) after switch maintenance avelumab (MAv) in the UNITE study","volume":"42","author":"Nizam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2025.05.014_bib0043","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"EV-302\/KEYNOTE-A39: open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392500208X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392500208X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T13:27:55Z","timestamp":1757338075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392500208X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S107814392500208X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.014","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.05.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}